Category: drug costs

KHN’s ‘What the Health?’: News You Might Have Missed

Congress is in recess, so the slower-than-average news week gives us a chance to catch up on underreported topics, like Medicare’s coverage decision for the controversial Alzheimer’s disease drug Aduhelm and ominous new statistics on drug overdose deaths and sexually transmitted diseases. Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico and the Johns Hopkins Bloomberg School of Public Health, and Alice Miranda Ollstein of Politico join KHN’s Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.

KHN’s ‘What the Health?’: Finally, a Fix for the ‘Family Glitch’

week to announce a new policy for the Affordable Care Act that would make subsidies available to more families with unaffordable employer coverage. Meanwhile, Congress struggled to find a compromise for continued federal funding of covid-19 vaccines, testing, and treatments. Tami Luhby of CNN, Shefali Luthra of The 19th, and Jessie Hellmann of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more.

Big Pharma Is Betting on Bigger Political Ambitions From Sen. Tim Scott

The South Carolina senator led the congressional pack in pharma campaign contributions for the second half of 2021. There are clear reasons.

Inside the Tactical Tug of War Over the Controversial Alzheimer’s Drug

An epic battle is playing out behind the scenes over whether the government should pay for Aduhelm, an FDA-approved Alzheimer’s drug that scientists say has not been proven to work.

I Write About America’s Absurd Health Care System. Then I Got Caught Up in It.

A KHN reporter had written for years about the people left behind by the absurdly complex and expensive U.S. health care system. Then he found himself navigating that maze as he tried to get his insulin prescription filled.

KHN’s ‘What the Health?’: Dealing With Drug Prices

Medicare officials tentatively plan to restrict the use of a controversial Alzheimer’s drug to only those patients participating in clinical trials, while the Department of Health and Human Services looks into lowering the monthly Medicare Part B premium. Meanwhile, covid confusion still reigns, as the Biden administration moves, belatedly, to make more masks and tests available. Joanne Kenen of Politico and the Johns Hopkins Bloomberg School of Public Health, Sarah Karlin-Smith of the Pink Sheet and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more.

KHN’s ‘What the Health?’: Manchin Blows Up Biden’s ‘Build Back Better’

Can’t see the audio player? Click here to listen on Acast. You can also listen on Spotify, Apple Podcasts, Stitcher, Pocket Casts or wherever you listen to podcasts. Sen. Joe Manchin (D-W.Va.) dashed the hopes of President Joe Biden and congressional Democrats for passage of the giant “Build Back Better” bill before the end of […]

KHN’s ‘What the Health?’: Oh, Oh, Omicron

Even before the omicron variant of covid starts to spread widely in the U.S., hospitals are filling up with post-holiday delta cases. Meanwhile, the Supreme Court signals — loudly — that 2022 will be the year it rolls back abortion rights in a big way. Margot Sanger-Katz of The New York Times, Alice Miranda Ollstein of Politico and Mary Ellen McIntire of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more.

KHN’s ‘What the Health?’: The Big Biden Budget Bill Passes the House

President Joe Biden’s social spending budget is on its way to the U.S. Senate, where Democratic leaders are (optimistically) hoping to complete work by the end of the year. Meanwhile, covid is surging again in parts of the country, along with the political divides it continues to cause. Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico and the Johns Hopkins School of Public Health, and Mary Agnes Carey of KHN join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner previews next week’s Supreme Court abortion oral arguments with Florida State University law professor Mary Ziegler.

Public Opinion Is Unified on Lowering Prescription Drug Prices. Why Are Leaders Settling for Less?

Politicians and many health experts have done their best to see the glass half-full in the plan put forward by congressional Democrats and the president. But it’s “a far cry” from what other nations do to rein in drug prices, and polls show most voters demand more protection.